导航切换
中国神经再生研究(英文版)
首页
关于本刊
编 委 会
在线投稿
期刊公告
出版道德
OA政策
联系我们
ENGLISH
INRS
数据库
神经退行性病
1.
Rapamycin reverses ferroptosis by increasing autophagy in MPTP/MPP+-induced models of Parkinson’s disease
(2023-05-05)
2.
Long-term radiofrequency electromagnetic fields exposure attenuates cognitive dysfunction in 5×FAD mice by regulating microglial function
(2023-05-05)
3.
Exosomes derived from human umbilical cord mesenchymal stem cells alleviate Parkinson’s disease and neuronal damage through inhibition of microglia
(2023-03-29)
4.
5-Hydroxytryptamine: a potential therapeutic target in amyotrophic lateral sclerosis
(2023-03-07)
5.
Single-nuclei RNA sequencing uncovers heterogenous transcriptional signatures in Parkinson’s disease associated with nuclear receptor-related factor 1 defect
(2023-03-07)
6.
Inhibiting 5-hydroxytryptamine receptor 3 alleviates pathological changes of a mouse model of Alzheimer’s disease
(2023-03-07)
7.
Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson’s disease
(2023-02-27)
8.
Emodin attenuates inflammation and demyelination in experimental autoimmune encephalomyelitis
(2023-01-12)
9.
A candidate protective factor in amyotrophic lateral sclerosis: heterogenous nuclear ribonucleoprotein G
(2023-01-12)
10.
Overexpression of fibroblast growth factor 13 ameliorates amyloid-β-induced neuronal damage
(2023-01-05)
11.
The relationship among amyloid-β deposition, sphingomyelin level, and the expression and function of P-glycoprotein in Alzheimer’s disease pathological process
(2023-01-05)
12.
Neural regeneration research model to be explored: SH-SY5Y human neuroblastoma cells
(2023-01-05)
13.
Blunt dopamine transmission due to decreased GDNF in the PFC evokes cognitive impairment in Parkinson’s disease
(2022-11-01)
14.
Neuroprotective effects of insulin-like growth factor-2 in 6-hydroxydopamine-induced cellular and mouse models of Parkinson’s disease
(2022-11-01)
15.
Neural progenitor cells derived from fibroblasts induced by small molecule compounds under hypoxia for treatment of Parkinson’s disease in rats
(2022-11-01)
16.
TMEM16F may be a new therapeutic target for Alzheimer’s disease
(2022-08-29)
17.
The Alzheimer’s disease-associated gene TREML2 modulates inflammation by regulating microglia polarization and NLRP3 inflammasome activation
(2022-07-20)
18.
Lactoferrin modification of berberine nanoliposomes enhances the neuroprotective effects in a mouse model of Alzheimer’s disease
(2022-06-17)
19.
DL-3-n-butylphthalide alleviates motor disturbance by suppressing ferroptosis in a rat model of Parkinson’s disease
(2022-06-17)
20.
Lamotrigine protects against cognitive deficits, synapse and nerve cell damage, and hallmark neuropathologies in a mouse model of Alzheimer’s disease
(2022-06-17)
21.
Icariin ameliorates memory deficits through regulating brain insulin signaling and glucose transporters in 3×Tg-AD mice
(2022-06-17)
22.
Dysregulated expression and distribution of Kif5α in neurites of wobbler motor neurons
(2022-06-17)
23.
Aquaporin 4 deficiency eliminates the beneficial effects of voluntary exercise in a mouse model of Alzheimer’s disease
(2022-03-10)
24.
Abnormal characterization of dynamic functional connectivity in Alzheimer’s disease
(2022-03-10)
25.
Endocannabinoid metabolism and Alzheimer’s disease
(2022-03-10)
26.
Glucose metabolism in amyotrophic lateral sclerosis: it is bitter-sweet
(2022-03-10)
27.
The blood-brain barrier models to study apolipoprotein E genotypes in Alzheimer’s disease
(2022-03-10)
28.
Perspective on the relationship between microbiota dysbiosis and neuroinflammation: probiotics as a treatment option
(2022-03-10)
29.
Is there a window of opportunity for the therapeutic use of vitamin D in multiple sclerosis?
(2022-03-10)
30.
Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer’s disease
(2022-03-10)
31.
Role of exosomes in the pathogenesis of inflammation in Parkinson’s disease
(2022-03-10)
32.
Intranasal neprilysin rapidly eliminates amyloid-beta plaques, but causes plaque compensations: the explanation why the amyloid-beta cascade may fail?
(2022-03-10)
33.
Crry silencing alleviates Alzheimer’s disease injury by regulating neuroinflammatory cytokines and the complement system
(2022-02-08)
34.
Phosphoinositide-3-kinase regulatory subunit 4 participates in the occurrence and development of amyotrophic lateral sclerosis by regulating autophagy
(2022-01-12)
35.
Propagation of TDP-43 proteinopathy in neurodegenerative disorders
(2022-01-12)
36.
Vibrotactile coordinated reset stimulation for the treatment of Parkinson’s disease
(2022-01-12)
37.
Impact of alpha-synuclein pathology on adult neurogenesis: evidence for multilayered mechanisms
(2022-01-12)
38.
Is activation of GDNF/RET signaling the answer for successful treatment of Parkinson’s disease? A discussion of data from the culture dish to the clinic
(2022-01-12)
39.
All roads lead to Rome — a review of the potential mechanisms by which exerkines exhibit neuroprotective effects in Alzheimer’s disease
(2021-12-17)
40.
Liposome based drug delivery as a potential treatment option for Alzheimer’s disease
(2021-12-17)
跳至
页
第1页
共6页
共224条记录
首页
上一页
下一页
尾页